Evidence map›Paper›PMID 24419387›Full record

ArticleActa crystallographica. Section D, Biological crystallography2014

Automating crystallographic structure solution and refinement of protein-ligand complexes.

Nathaniel Echols, Nigel W Moriarty, Herbert E Klei, Pavel V Afonine, Gábor Bunkóczi, Jeffrey J Headd, Airlie J McCoy, Robert D Oeffner, Randy J Read, Thomas C Terwilliger and 1 more

Abstract read
In one paragraph

Article in Acta crystallographica. Section D, Biological crystallography, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Protein X-ray Crystallography and Drug Discovery.Molecules (Basel, Switzerland) · 2020
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nathaniel EcholsPhysical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720-8235, USA.
Nigel W MoriartyPhysical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720-8235, USA.
Herbert E KleiPhysical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720-8235, USA.
Pavel V AfoninePhysical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720-8235, USA.
Gábor BunkócziDepartment of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Cambridge CB2 0XY, England.
Jeffrey J HeaddPhysical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720-8235, USA.
Airlie J McCoyDepartment of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Cambridge CB2 0XY, England.
Robert D OeffnerDepartment of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Cambridge CB2 0XY, England.
Randy J ReadDepartment of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Cambridge CB2 0XY, England.
Thomas C TerwilligerLos Alamos National Laboratory, Los Alamos, NM 87545-0001, USA.
Paul D AdamsPhysical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720-8235, USA.

Funding

PROJECT 5 - DUKE - STRUCTURE VALIDATION AND IMPROVEMENT FOR PROTEINS AND N. ACIDSP01GM063210 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI ADAMS, PAUL DAVID · 2001 to 2021
$33.5M
NIGMS NIH HHS 1P01 GM063210NIGMS NIH HHS P01 GM063210Wellcome Trust 082961Wellcome Trust 100140
6 · The paper itself

Abstract

High-throughput drug-discovery and mechanistic studies often require the determination of multiple related crystal structures that only differ in the bound ligands, point mutations in the protein sequence and minor conformational changes. If performed manually, solution and refinement requires extensive repetition of the same tasks for each structure. To accelerate this process and minimize manual effort, a pipeline encompassing all stages of ligand building and refinement, starting from integrated and scaled diffraction intensities, has been implemented in Phenix. The resulting system is able to successfully solve and refine large collections of structures in parallel without extensive user intervention prior to the final stages of model completion and validation.

Indexed as

AnimalsCrystallography, X-RayDrug DesignFactor XaHIV-1HIV ProteaseHumansLigandsModels, MolecularProtein BindingProteinsThrombinFactor XaHIV ProteaseLigandsp16 protease, Human immunodeficiency virus 1ProteinsThrombinautomationcrystallographic structure solution and refinementprotein–ligand complexes

Identifiers

PMID24419387
PMCPMC3919266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.